INTERNATIONAL PATENT: BRIGHTPATH BIOTHERAPEUTICS CO., LTD., ブライトパス・バイオ株式会社 FILES APPLICATION FOR "MULTISPECIFIC ANTIGEN-BINDING MOLECULE TARGETING CD39"

GENEVA, April 7 -- BRIGHTPATH BIOTHERAPEUTICS CO., LTD. (3-25-22 Tonomachi, Kawasaki-ku, Kawasaki-shi, Kanagawa2100821), ブライトパス・バイオ株式会社 (神奈川県川崎市川崎区殿町３－２５－２２) filed a patent application (PCT/JP2024/034478) for "MULTISPECIFIC ANTIGEN-BINDING MOLECULE TARGETING CD39" on Sep 26, 2024. With publication no. WO/2025/070636, the details related to the patent application was published on Apr 03, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed...